301. [Assessment of a self-administered questionnaire identifying occupational exposures among lung cancer patients].
- Author
-
Varin M, Charbotel B, Pérol O, Perrier L, Massardier-Pilonchéry A, Bonnand S, Belladame E, Fort E, Avrillon V, Rebattu P, Pérol M, and Fervers B
- Subjects
- France epidemiology, Humans, Lung Neoplasms diagnosis, Occupational Diseases diagnosis, Referral and Consultation statistics & numerical data, Sensitivity and Specificity, Time Factors, Lung Neoplasms epidemiology, Occupational Diseases epidemiology, Occupational Exposure statistics & numerical data, Surveys and Questionnaires, Workers' Compensation
- Abstract
Ten to 29% of lung cancers might be linked to occupational factors but 60% of them are not compensated. The PROPOUMON project aimed to improve the identification, recognition and compensation of occupational lung cancer as occupational disease using a self-administered questionnaire (AQREP). One objective was to assess the AQREP, comparing it with the questionnaire drawn up by the French Language Pneumology Society (Q-SPLF). From March 2014 to September 2015, 90 lung cancer patients treated at the Centre Léon-Bérard responded to the AQREP and Q-SPLF. The two physicians in charge of the consultation assessed independently whether or not a consultation was indicated. A certificate for the compensation process was proposed when a suspicion of high or average imputability was identified. Analysis of the questionnaires was concordant for 73% of the patients. The AQREP has a sensitivity of 72% and a specificity of 73%. Its positive and negative predictive values were 62 and 82%. The information provided by 24 patients were discordant between questionnaires. In two patients with discordant evaluation (AQREP+/Q-SPLF-; AQREP-/Q-SPLF+), one Initial Medical Certificate (IMC) was written. This study made it possible to conclude that AQREP is relevant for the identification of potentially occupational lung cancers. Collegial discussion of complex cases might be considered. The project is currently been extended to other centers and to lymphoma., (Copyright © 2017 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF